2 active not recruiting, 1 recruiting, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 2, Terminated 1 |
Follow John Rieth: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Intralesional Injection of Talimogene Laherparepvec Talimogene Laherparepvec, Neoadjuvant Radiation, Surgery - Soft Tissue Sarcoma, Sarcoma,Soft Tissue | Phase 2 | Active not recruiting | John Rieth | 2 | 2025-03-03 | 2026-07-17 |
| Palbociclib and Pembrolizumab in Sarcoma Palbociclib, Pembrolizumab - Sarcoma | Phase 1 | Recruiting | John Rieth | 8 | 2024-02-01 | 2026-05-22 |
| TVEC and Preop Radiation for Sarcoma (8 ml Dose) Talimogene Laherparepvec, Radiotherapy - Soft Tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | John Rieth | 8 | 2020-09-10 | 2026-01-29 |
| Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma Cabozantinib, Pembrolizumab - Advanced Metastatic Melanoma | Phase 1 / Phase 2 | Terminated | John Rieth | 28 | 2019-08-27 | 2026-01-29 |
Sarcoma (3)
pembrolizumab (2) · talimogene laherparepvec (2) · Neoadjuvant Therapy (1) · Radiotherapy (1) · Surgical Procedures, Operative (1) · cabozantinib (1) · palbociclib (1)
United States (4)